{
  "asset": {
    "name": "TransCon IL-2 \u03b2/\u03b3",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "Interleukin-2",
    "mechanism": "TransCon prodrug releasing IL-2",
    "modality": "TransCon prodrug",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Phase 2",
    "indications_in_development": [
      "Various tumor types",
      "Platinum-resistant ovarian cancer"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [
    {
      "event": "TransCon IL-2 \u03b2/\u03b3 IL-Believe program update (PROC OS)",
      "timing": "Q4 2026"
    }
  ],
  "_source_pages": [
    6,
    7,
    29
  ],
  "_last_extracted": "2026-02-04T13:33:12.101312"
}